Koios Medical vs ScreenPoint Medical
Updated October 20, 2026
AI software now helps radiologists find breast cancer earlier and decide which findings need a biopsy, and many breast centers are pricing it for the first time. Koios Medical and ScreenPoint Medical both sell breast cancer AI, yet they work on different exams: ScreenPoint reads the screening mammograms most women get, while Koios reads the ultrasound done after something looks suspicious. Many centers could use both, so we compared where each one fits and how strong its evidence is.
Our analysts compared Koios Medical and ScreenPoint Medical on the exams each reads, what the software does, clinical evidence, workflow fit, and pricing clarity, using the HIR review of each company and ScreenPoint's own announcements this year. In the following sections, we compare them in one table, describe the imaging program each one suits, and list what ScreenPoint has announced recently.
Koios Medical vs ScreenPoint Medical at a glance, October 2026
| What buyers weigh | Koios Medical | ScreenPoint Medical |
|---|---|---|
| Pricing model | A software license for FDA-cleared ultrasound AI, priced by site and volume. | Subscription quoted by ScreenPoint Medical or through imaging partners. |
| What drives cost | The number of sites, exam volume, breast or thyroid modules, and how it connects to your systems. | Exam volume, 2D or 3D mammography, the number of sites, and whether it is bought directly or through a PACS or imaging equipment partner. |
| Exams it reads | Breast and thyroid ultrasound. | Screening mammograms and 3D tomosynthesis exams. |
| What the software does | Gives readers a second opinion on breast lesions and thyroid nodules to guide biopsy decisions. | Marks areas that may be cancer and scores each exam from 1 to 10, so radiologists can read the riskiest exams first. |
| Clinical evidence | A real clinical niche, with limited public proof that it works at large scale. | Final results of the MASAI randomized trial in Sweden, published in The Lancet in January 2026, favored it against double reading by two radiologists. Clear edge |
| FDA clearance | FDA-cleared decision support for breast and thyroid ultrasound. | FDA-cleared, though the clearance does not cover ruling out normal exams without a radiologist. |
| Reach | Little is public about how widely it is sold. | Used in more than 30 countries, including at Johns Hopkins. |
| Clinical results | Scores 6.9 on usefulness in its cleared uses. | Scores 8.4 on cancers found and reading time saved. Higher score |
| Fitting into reading work | Scores 6.3 on device and reporting rollout. | Scores 7.6 on fitting into the reading workflow. Higher score |
| Time to full value | Not published | About 7 to 16 months |
| What you need first | A radiology lead for ultrasound and imaging IT time to connect PACS, RIS, and the EMR. | A lead breast radiologist and a connection to the reading workstation and PACS. |
| Deal-breaker | Your site has nobody to own the rollout or the system connections. | You expect the AI to read exams on its own in the US. |
| Pricing clarity score | 6.4 | 7.1 Clearer pricing |
| HIR overall score | 6.7, Conditional. | 7.9, Recommend. Higher score |
| Best for | Breast and thyroid ultrasound programs that want FDA-cleared AI to act as a second reader. | Breast imaging centers and radiology groups that read large volumes of screening mammograms and tomosynthesis exams. |
| Not a fit for | Radiology groups whose main purchase is CT and MRI triage across the whole system. | Groups that want one AI vendor for chest, brain, and bone imaging. |
Which fits which buyer
Start with the exam where your readers need the most help.
Choose Koios Medical if
- Your breast or thyroid ultrasound readers want a consistent second opinion.
- You plan to track how many biopsies find cancer and how often readers agree.
- Your thyroid nodule work needs decision support too.
Choose ScreenPoint Medical if
- You read a large volume of screening mammograms or tomosynthesis exams.
- You want AI backed by a randomized trial.
- You want a risk score on each exam so the riskiest are read first.
Verdict
ScreenPoint Medical scores far higher and fits breast screening programs that want trial-backed AI in mammography reading. Koios Medical fits ultrasound programs that want a second reader for breast and thyroid findings and will track results locally.
The two cover different exams, so a center that buys ScreenPoint can still weigh Koios for ultrasound.
Where the two tools are headed in 2027 and beyond
ScreenPoint Medical: ScreenPoint Medical made Transpara available through Ferrum Health's AI governance platform on January 13, 2026. It raised new funding from Insight Partners and Siemens Healthineers on April 17, 2026, along with research grants, to expand its breast cancer work.
Ask ScreenPoint which parts of the Transpara suite are cleared for US use at your site.
Methodology
Each row comes from the HIR reviews of Koios Medical and ScreenPoint Medical, scored under the HIR method, and from each vendor's public pricing where it exists. Any published price for Koios Medical or ScreenPoint Medical was checked on that vendor's own site on October 20, 2026.
A green check marks a clear edge for Koios Medical or ScreenPoint Medical only where their review scores differ by at least 0.3 points or the two reviews show a plain difference. Rows with nothing published for either Koios Medical or ScreenPoint Medical are left out, and time to full value for each adds up the rollout stages in its review.
Sources
- HIR review of Koios Medical and HIR review of ScreenPoint Medical
- ScreenPoint Medical and Ferrum Health partner, January 13, 2026
- MASAI trial final results, January 30, 2026
- ScreenPoint Medical funding announcement, April 17, 2026
- Koios Medical website